Could less radiation be enough for HPV throat cancer?

NCT ID NCT05268614

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study is testing whether giving less radiation, based on a patient's HPV type and levels of HPV DNA in the blood, can control throat cancer as well as standard higher doses. About 250 adults with favorable-prognosis oropharyngeal cancer will receive 70, 60, or 50 gray of radiation depending on their risk profile. The goal is to maintain cancer control while reducing treatment side effects.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Radiation therapy (dose adjusted based on HPV subtype and DNA levels)
What this could lead to
If successful, this could show that many patients with HPV-related throat cancer can safely receive lower doses of radiation, reducing side effects while still controlling the cancer.
What could go wrong
This is a Phase 2 trial with 250 participants, so results are not yet proven. There is a risk that lower radiation doses may not control the cancer as well as standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

oropharynx squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Medical University of South Carolina

    RECRUITING

    Charleston, South Carolina, 29425, United States

  • UF Health Proton Therapy Institute

    RECRUITING

    Jacksonville, Florida, 32206, United States

  • University of Florida

    RECRUITING

    Gainesville, Florida, 32610, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.